In a recent analysis of metabolic scaling in solid tumours we found a scaling law that interpolates between the power laws µ ∝ V and µ ∝ V 2/3 , where µ is the metabolic rate expressed as the glucose absorption rate and V is the tumour volume. The scaling law fits quite well both in vitro and in vivo data, however we also observed marked fluctuations that are associated with the specific biological properties of individual tumours. Here we analyse these fluctuations, in an attempt to find the population-wide distribution of an important parameter (A) which expresses the total extent of the interface between the solid tumour and the non-cancerous environment. Heuristic considerations suggest that the values of the A parameter follow a lognormal distribution, and, allowing for the large uncertainties of the experimental data, our statistical analysis confirms this.
Introduction
The allometric laws of biology are power laws that describe in simple and universal terms some of the features that are common to the vast diversity of living organisms [1, 2, 3] . Their simplicity hides the ambitious aim of encapsulating in a single equation the huge variability and diverse dynamics that 5 belong to living systems. Sometimes, their purely empirical character has produced controversy, and some of these laws are not universally accepted [4, 5, 6 ].
Kleiber's law is one such scaling law: it states that the basal metabolic rate of an organism of mass M scales as M 3/4 = M 0.75 [7] instead of the naive estimate M 2/3 ≈ M 0.67 , and it has both supporters and opponents. Kleber's law has long 10 been mysterious and only in recent years it has found the backing of a biological argument based on fractal structure of microcirculation [8] , which is however still controversial [9, 10, 11, 11] . Nonetheless, the law has been applied also outside the domain of validity of the supporting argument, as in the case of the metabolism of solid tumours [12] . Indeed, microcirculation in tumour tissues 15 is quite different from normal tissues, with an ensuing wide-ranging variability of cellular phenotypes and local microenvironments. However, it is well-known that there is a strong correlation between tumour microenvironment and aggressiveness, and this provides a strong motivation to study the microscopic origin of any metabolic scaling law that may arise in this context.
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We have recently proposed a metabolic scaling law for solid tumours that describes quite well both in vitro and in vivo experimental data (see figure 1) [13] . Its peculiarity is that it has been obtained with the help of a computational description of metabolism at the single-cell level which provides the link with the microscopic features of tumours [14, 15, 16] . The law is not quite a power law, and it is given by the following expression:
where µ is the metabolic rate expressed as the glucose absorption rate, V is the tumour volume, v c is the mean cell volume, c is the cell-specific consumption rate of a single cell [13] , and A is a non-dimensional parameter whose meaning will be clarified below. The λ parameter is a characteristic length in an exponential law that describes the decay of the fraction of live cells with increasing distance from the blood vessels (see [16] for details). The ratio η = c/v c in equation (1) is independent of cell size, since c is roughly proportional to cell volume. Equation (1) shows that the metabolic rate interpolates between the two power-laws
at small volume and
at large volume, and if we take the middle value of the exponent (0.84) we note that it is not very far from the exponent of Kleiber's law.
Turning to parameter A, we note that is related to the total extent of the interface between solid tumour and surrounding environment, see fig.2 : if x is a diameter (chosen between two recognizable features of the tumour) then the 25 total interface area S scales as S = Ax 2 (see also ref [13] ). The analysis of existing data -both in vitro and in vivo -points to a strong dependence of the metabolic rate on A. In particular, we attribute the spread of data about the theoretical expression shown in figure 1 to the fluctuations of A in populations of histologically similar tumours. Since the interface area of a tumour with the 30 normal tissue environment influences both its growth rate and its metastatic potential, these fluctuations are clinically relevant.
In this paper we argue that the probability distribution of A is lognormal, and we show that the experimental data support this conjecture.
Theory
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The A parameter is directly related to the complexity of the interface between tumour and environment (see figure 2) , and the interface growth can be pictured as a gradual buildup of new features that appear on already existing elements, in a way that is multiplicative rather than additive -as in a Kolmogorov process [17] . Such a process has already been assumed in simple simulations of biological growth based on analogs of diffusion limited aggregation [18, 19] , and if growth can be mapped on a Kolmogorov process this leads to a lognormal distribution [17, 20, 21] p(A; m, σ) = 1
where m and σ are the parameters that define the shape of the distribution.
This type of growth has already been used in an attempt to explain the complex structure of human lungs [22] . In this section we demonstrate the plausibility of the lognormal conjecture and show how to obtain values of A from the data shown in figure 1. In this case the conjecture that the A parameter follows a lognormal distribution is made plausible by the following considerations. In a solid tumour with total volume V and total interface area S, the interface corresponds to all the surface where tumour cells exchange oxygen, nutrients and metabolites with the environment, and can be identified with the set of blood vessels that traverse the tumour mass. This corresponds to a large area, and if we make the simplifying assumption that the radius r of blood vessels is fixed, then it is given by S ≈ 2πrL, where L is the total length of the blood vessel network.
When the linear size of the volume increases by a factor α, we find that the volume increases by a factor α 3 and the surface area by a factor α 2 , however this also means that the total length of the blood vessel network also increases by the same factor α 2 . This tells us that blood vessels sprout new vessels, and the contribution of these new blood vessels to the total network length is the difference between the quadratic growth and a simpler linear growth
The same reasoning works also in the more general case where the growth of the interface area is not exactly quadratic, but has a fractional exponent S = α β S, then the contribution of new vessels to the growth of the network length is
Whatever the case, there cannot be a continuos growth, and the evolution of the tumour mass must be punctuated by discrete sprouting events, with a random distribution of α at each step. We can also write
in the case of growth over many sprouting events, where subscripted values are fixed at a given time t 0 , or also
for growth between two sprouting events. Then we see from this equation that the actual value of A at any given time fluctuates about an average, and that it is given by
where α is the combined, multiplicative result of many blood vessel sprouting events. This means that
so that ln A is a (large) sum of variates, and if the assumptions of the central limit theorem hold, then A has a lognormal distribution.
The case of in vitro tumour spheroids
The previous considerations do not apply to avascular tumours like the tumour spheroids, however we can pinpoint processes that contribute to a sim-50 ilar multiplicative structure in the determination of the actual interface area.
Indeed, it has long been known that tumour spheroids grown in identical conditions can have widely differing sizes at saturation [23, 24] , and that this is closely related with the spheroid structure, in particular with the formation of the necrotic core: this fact underscores the importance both of the random 55 events at the single-cell level -the only difference in the development of these spheroids -and of the structural elements. Another hint is provided by observations of the surface of tumour spheroids, which is often rough and marked by hills and valleys; this fact has recently been exploited in a study of the delivery of nanoparticles into tumour tissue [25] . Irregularities such as these are again 60 the result of discrete and at least partially random events, like cell death in the necrotic core and the mitoses in the outer cell layer of tumour spheroids, and the previous reasoning applies again -although we expect to find a lognormal distribution with different parameters.
Finding A from metabolic data
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Here we remark that we can use the metabolic scaling law to determine A when the other parameters are fixed
and we do so both for cultured tumour spheroids, where it is easier to estimate η, and for human tumours, using an average η. For a given histological type, both η and λ are nearly fixed, and here we take the values of λ estimated in [13] for tumour spheroids and for human tumours. Because of the difficulty of obtaining valid data, we also use the same datasets of [13] , that we selected 70 after an extensive search of the existing literature. And indeed, while there are many data available, their usability is limited by the following requirements:
• we utilise glucose absorption to define the metabolic rate; therefore all the data used in equation (1) or (11) must refer to glucose;
• it is difficult to find combined values of the parameters for the same cell without any reference to the total amount of tissue used.
Calculation
We used the procedure of section 2.2 to obtain the A values corresponding to the data shown in figure 1. Since these data are affected by rather large uncertainties, the complete probability density function (pdf) of each measurements is the convolution of the lognormal distribution with a normal distribution (we make the usual assumption that measurement uncertainties have a normal distribution):
dx (12) where σ 0 is the measurement error. Then the complete log-likelihood is
where (13) is only approximate because the large measurement errors on A cannot be Gaussian -A is a non-negative parameter -and moreover it depends strongly on the specific measurement errors σ 0 (i). Moreover, we have only incomplete information on the measurement themselves and could not obtain good error estimates for many datapoints. All
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of this leads to large numerical uncertainties and to inconclusive results when using the log-likelihood (13) , so that eventually we opted to fit the values A deduced with (11) with the lognormal pdf (4), and our results are also shown in figures 3 and 4.
We tested the validity of the lognormal hypothesis by comparing it with 95 a highly flexible phenomenological model, a Gaussian mixture model with a variable number of components. We did this in a Bayesian framework, and we ranked the different hypotheses using marginal likelihoods, both for cultured spheroids and for solid tumours.
In the case of cultured spheroids we considered a total of 35 alternative 100 models, the lognormal model and 34 Gaussian mixture models with a number of components ranging from 1 to 34. We defined only 34 mixture models because the data set contains 34 samples, and therefore any more complex model would glucose uptake values given in [13] we have used η = 6.5 × 10 −12 and λ = 93.9 µm for 9L spheroids, η = 4.2 × 10 −12 and λ = 123.6; µm for Rat-T1 spheroids; η = 8.9 × 10 −12 and λ = 91.0 µm for MR1 spheroids. The solid curve is the lognormal fit, the dashed line is the empirical smoothed kernel density, and the dotted line is a power-law with exponent -1.3. 
Model 1.
. . .
Model 34.
where logN(A; m, σ) is the lognormal pdf with parameters m and σ as above, and N(A; m, σ) is the normal pdf with parameters m and σ.
We introduced weakly informative priors for these models. For the lognormal one, m and σ were assigned uniform priors from 0 to 200. For the mixture models
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of M components, we assigned M − 1 uniform priors for α i in the interval 0 to 1, added an extra improper prior for To rank alternative hypotheses, we need to estimate marginal likelihoods 115 for the alternative models. We estimated these likelihoods using the Thermo- data. Notice that the lognormal model fares better than the large majority of the highly flexible Gaussian mixture models and in contrast to all of them it is biologically motivated.
V L A D V Y S H E M I R S K Y
and i to be independent and uniformly distributed from 0 to 200, finally, we add an improper order prior for µ 1  µ 2  . . .  µ M .
Estimating Marginal Likelihoods
To rank alternative hypotheses, we need to estimate marginal likelihoods for the alternative models. We estimated these likelihoods using the Thermodynamic Integration method proposed by (N. Friel et al., 2008) , and obtained the results listed in Table 1 . These results produce relative model probabilities as depicted in the following chart:
Together with the Bayes factor for preferring the log-normal model over any of the mixture models having the value of 4.448077 ⇥ 10 18 , this indicates decisive evidence that the log-Normal model should be preferred over any mixture of gaussians. 
Results and Discussion
As noted above, the A parameter is related to the overall shape of the tu-135 mour. It is one of the factors that set the timescale of tumour growth and has an importance of its own, as it determines both the total tumour volume and the size of the interface between tumour and nutrient-supplying blood vessels. This interface also regulates the influx of drugs and influences the overall metastatic potential because it is the place where tumour cells can enter the blood stream.
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The heuristic considerations discussed above suggest that tumour spheroids and 
Conclusions
The A parameter sets the extent of the interface area, and for this reason it has an obvious correlation with tumour aggressiveness and with the structure of 
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